Medicare AdvantageCoverageMedium impact
MA06.014e, Pharmacogenetics and Metabolite Monitoring for Using Azathioprine (AZA)/6-Mercaptopurine (6-MP) Therapy
Independence Blue Cross·Gastroenterology, Rheumatology, Oncology +1 more·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.014e for pharmacogenetics and metabolite monitoring related to Azathioprine/6-Mercaptopurine therapy has been reissued with updates effective October 1, 2025. This affects billing and coverage for genetic testing and monitoring services related to these immunosuppressive medications.
Action Required
By October 1, 2025: Billing team must review updated policy MA06.014e for pharmacogenetics and metabolite monitoring requirements for Azathioprine/6-Mercaptopurine therapy. Verify current billing practices align with new Medicare Advantage coverage criteria. Contact Medicare Advantage plans to clarify any changes to prior authorization or documentation requirements for genetic testing related to these medications.